Ranked among the top 5% in the industry, Healthy Yuan's S&P Global ESG rating has once again achieved a high score and been included in the list.

Time Posted：2025-01-21 14:00

Recently, the results of the S&P Global Sustainability Assessment were released. Health Yuan (600380.SH) stood out with its excellent Environmental, Social, and Governance (ESG) performance. In the 2024 S&P Global Corporate Sustainability Assessment, it achieved a score of 69, surpassing 95% of its peer companies and ranking third among participating pharmaceutical companies in China.

The Jiankangyuan PREP target COPD innovative drug project has entered a phase I bridging healthy subject study.

Time Posted：2025-01-13 14:52

Recently, HealthGen's PREP-targeted COPD innovative drug project has achieved a key milestone. This drug is expected to become China's first innovative mechanism oral COPD drug and has officially entered the "Phase 1 bridging healthy subject study". This marks a significant step in the project's transition from research and development to clinical application, laying a solid foundation for the future launch of the new drug.

Health Yuan's new drug is about to be launched, and the anti-influenza market landscape may change.

Time Posted：2025-01-07 16:15

With the arrival of the influenza season, influenza cases have risen sharply in many parts of the country recently. Disease control departments have issued urgent reminders that the positive rate of influenza A virus continues to climb, with over 99% being influenza A. Influenza, as an acute respiratory infectious disease, brings enormous public health pressure to the world every year due to its rapid spread and strong infectivity. It poses a serious threat to children, the elderly, and people with weakened immune systems.

Safer and More Effective: Health Yuan's Novel β-Lactamase Inhibitor Injection Ushers in an Upgrade for Infection Treatment

Time Posted：2025-01-02 14:37

Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Health Yuan") has launched China's first and the world's only novel β-lactamase inhibitor injection for combined use with meropenem. The launch of this innovative drug not only consolidates Health Yuan's leading position in the field of anti-infection, but also marks a comprehensive upgrade of its global R&D strategy, providing a revolutionary treatment option for combating antibiotic resistance.

Behind the "surprise attack" of Jiankangyuan on the tens of billions of flu market

Time Posted：2024-12-18 18:00

Mapasivav's arrival is quite "seasonal". In early December, the National Pharmacopoeia Committee approved the generic name "Mapasivav" for the influenza drug developed by Health and Wellness (600380.SH). This means that the blockbuster new drug, which Health and Wellness considers a "milestone", is very close to its official launch.

Good news! CSPC Pharmaceutical's semaglutide injection has completed enrollment of all cases in the Phase III clinical trial for weight management indication.

Time Posted：2024-12-03 16:54

Good news on R&D innovation. Recently, the Phase III clinical trial for the weight management indication of semaglutide injection developed by New Bei Jiang Pharmaceutical Co., Ltd., a subsidiary of Lizhu Group, has completed enrollment of all cases. The rapid advancement of the clinical trial has laid a solid foundation for the drug's launch.

Health Yuan launches innovative inhaled PDE4 inhibitor, promoting new breakthroughs in the treatment of COPD and asthma

Time Posted：2024-11-25 17:29

Recently, the world welcomed the 23rd World Chronic Obstructive Pulmonary Disease Day (COPD Day). While many patients suffer from this disease, many innovative pharmaceutical companies are deploying resources in this field and continuously achieving new breakthroughs. Health Yuan Pharmaceutical Group, a leading domestic respiratory preparation company, has launched another innovative drug – an inhaled PDE4 inhibitor for chronic obstructive pulmonary disease (COPD). This marks a further expansion of the company's innovative R&D layout in the respiratory field. COPD is a common chronic respiratory disease that damages patients' lungs and leads to progressive decline in lung function. Moderate to severe COPD is often accompanied by persistent inflammation. This inflammation not only exacerbates airway obstruction but also further accelerates the disease progression. Currently, the main anti-inflammatory respiratory treatment drugs for COPD management on the market are corticosteroids (ICS). For moderate to severe patients, especially those with acute exacerbations, their therapeutic effect is limited. Innovative Inhaled PDE4 Inhibitor: Precisely Targeting COPD Inflammatory Cells and Reducing Side Effects PDE is short for phosphodiesterase, a type of enzyme, similar to a "cleaner" in the human body. Its family members are numerous and have clear divisions of labor. In recent years, the medical community has discovered, through extensive research, a more selective PDE family, mainly PDE4, which can precisely target inflammatory cells in COPD. Because of its anti-inflammatory activity, some experts believe that long-term use may improve lung function in severe COPD patients and reduce the frequency of acute exacerbations. In the past, many international pharmaceutical companies have vigorously developed PDE4 inhibitors, such as the oral COPD drug roflumilast. However, although past results have shown some efficacy in improving lung function and reducing acute exacerbations, its systemic administration has led to significant side effects, such as diarrhea, nausea, abdominal pain, sleep disorders, and headaches, which have to some extent limited its widespread clinical application. Against this backdrop, there is an urgent clinical need for a new inhaled PDE4 inhibitor. Health Yuan's newly launched inhaled PDE4 inhibitor, due to its local administration, can reduce systemic side effects while retaining efficacy. This is also the first PDE4 inhaled formulation pipeline launched by a Chinese company. Effectively Reducing the Frequency of COPD Exacerbations Data show that compared with oral PDE4 drugs, this innovative inhaled agent, through inhalation, maintains high levels of intracellular cAMP, effectively inhibiting the release of inflammatory factors, reducing protease activity and oxidant production, creating a strong anti-inflammatory environment, and significantly alleviating inflammatory symptoms in COPD patients. While significantly reducing systemic drug exposure, it also reduces the risk of systemic side effects, ensuring treatment safety. This innovative inhaled inhibitor, as a drug with a novel mechanism in the COPD field, directly targets lung lesions through anti-inflammation, improvement of lung function, and modulation of immune responses, effectively reducing the frequency of COPD exacerbations, and is expected to bring new therapeutic hope to patients in this field. At the same time, the broad-spectrum anti-inflammatory properties of PDE4 inhibitors also show potential in the treatment of asthma and other diseases. It is reported that PDE4 inhibitors, by continuously maintaining high levels of intracellular cAMP, can effectively inhibit T cell activation and regulate inflammatory cell function. In addition, it can comprehensively inhibit the release of inflammatory factors, reduce protease activity and oxidant production, creating a strong anti-inflammatory environment, opening up new possibilities for the treatment of asthma patients and other related diseases, and demonstrating its broad prospects in the treatment of respiratory diseases. Health Yuan's Respiratory Strategy As a leading enterprise in China's inhaled formulation field, Health Yuan has always regarded the inhaled formulation sector as one of the core elements of the company's strategic development. The company continues to increase investment in independent R&D and actively introduces and develops advanced innovative drugs at home and abroad, continuously enriching its Big Pharma-level product pipeline. Currently, Health Yuan has successfully launched 10 varieties and 14 specifications of respiratory products to the market, and has a reserve of more than 20 research varieties, including 10 innovative respiratory drugs, achieving full coverage of asthma and COPD inhaled treatment drugs, and building a comprehensive layout from existing mature products to future potential new drugs. The launch of the inhaled PDE4 inhibitor will further enrich Health Yuan's innovative drug pipeline in the respiratory field and consolidate the company's leading position in the respiratory field. At the same time, Health Yuan will make every effort to promote the R&D process of this innovative drug, striving to transform it into a clinical treatment plan as soon as possible, and contribute more "healthy" power to the prevention and control of COPD in China and even the world.

Health Yuan and Qi Yuan Bio have reached a new drug licensing cooperation for an inhaled PDE4 inhibitor, jointly promoting innovative drug development.

Time Posted：2024-11-25 14:38

On November 22, 2024, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare"), an innovative research-oriented comprehensive pharmaceutical group, and QiYuan Bio (Hangzhou) Co., Ltd. (hereinafter referred to as "QiYuan Bio"), which focuses on the development of innovative drugs for autoimmune diseases, jointly announced that the two parties have reached a licensing cooperation agreement for an innovative drug—an inhaled PDE4 inhibitor for chronic obstructive pulmonary disease (COPD). According to the agreement, Joincare obtains the right to develop and commercialize this innovative drug in China, while QiYuan Bio retains the right to develop the topical cream. Both parties will jointly promote the development and market promotion of this innovative drug. This innovative PDE4 inhibitor, as a drug with a novel mechanism in the field of COPD, can precisely act on COPD inflammatory cells, and effectively reduce the frequency of acute COPD exacerbations through multiple mechanisms such as anti-inflammation, improvement of lung function, and regulation of immune response. The inhaled administration significantly reduces systemic drug exposure, ensuring treatment safety while reducing the risk of systemic side effects. This is also the first PDE4 inhaled formulation pipeline launched by a Chinese company. In addition, the broad-spectrum anti-inflammatory properties of PDE4 inhibitors also show therapeutic potential for diseases such as asthma.